SWOG clinical trial number
S1417CD

Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer

Closed
Phase
Accrual
100%
Abbreviated Title
Impact of Cancer on Finances
Activated
04/15/2016
Closed
02/01/2019
Participants
ALL NCORP COMPONENTS AND SUBCOMPONENTS

Research committees

Cancer Care Delivery
Gastrointestinal Cancer

Eligibility Criteria Expand/Collapse

Patients must have newly diagnosed metastatic colon or rectal cancer (mCRC) (de novo metastatic diagnosis) or metastatic recurrence after prior treatment for Stage I-III disease and be within 120 days after diagnosis at time of registration;Systemic chemotherapy and/or systemic biologic therapy must be planned to be administered </= 30 days after registration OR must have been initiated </= 60 days prior to registration. Patients who are planning palliative or hospice care only (no chemotherapy or biologic therapy) are not eligible; must be at least 18 years of age; It is recommended that patients receive medical care for the mCRC at the registering site to ensure accessibility of patient records during follow-up; must be able to complete questionnaires in English.

Publication Information Expand/Collapse

2022

S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients

V Shankaran;J Unger;A Darke;J Suga;J Wade;P Kourlas;S Chandana;M O'Rourke;S Satti;D Liggett;D Hershman;S Ramsey Journal of the National Cancer Institute Mar 8;114(3):372-380; Jan 4;djab210. doi: 10.1093/jnci/djab210. Online ahead of print.

PMid: PMID34981117 | PMC number: PMC8902339

2020

Design, Data Linkage, and Implementation Considerations in the First Cooperative Group Led Study Assessing Financial Outcomes in Cancer Patients and their Informal Caregivers

V Shankaran;J Unger;A Darke;DL Hershman;SD Ramsey Contemporary Clinical Trials Aug;95:106037. doi: 10.1016/j.cct.2020.106037. Epub 2020 May 30.

PMid: PMID32485324 | PMC number: PMC8171354

Cumulative Incidence of Financial Hardship in Metastatic Colorectal Cancer (mCRC) Patients (pts): Primary Endpoint Results for SWOG S1417CD

V Shankaran;J Unger;A Darke;J Suga;J Wade;P Kourlas;S Chandana;M O'Rourke;S Satti;D Liggett;D Hershman;S Ramsey J Clin Oncol 38: 2020 (suppl; abstr 7010); American Society of Clinical Oncology 2020 Annual Meeting, poster discussion

Cumulative Incidence of Financial Hardship in Metastatic Colorectal Cancer (mCRC) Patients (pts): Primary Endpoint Results for SWOG S1417CD

V Shankaran;J Unger;A Darke;J Suga;J Wade;P Kourlas;S Chandana;M O'Rourke;S Patti;D Liggett;D Hershman;S Ramsey J Clin Oncol 38: 2020 (suppl; abstr 7010); ASCO Quality Care Symposium (October 9-10, 2020, Virtual), oral

2019

Design and Accrual of SWOG S1417CD: Development of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer (mCRC)

V Shankaran;J Unger;A Darke;JM Suga;JL Wade;P Kourlas;S Chandana;M O'Rourke;S Satti;D Liggett;D Hershman;S Ramsey J Clin Oncol 37(suppl; abstr TPS6652); American Society of Clinical Oncology (5/31/19-6/4/19, Chicago IL), TIPS, poster session

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
83%
Open
Phase